6. Stereotaxis, Inc. (NYSEAMERICAN:STXS)
Number of Hedge Fund Holders: 10
Upside Potential: 185.70%
Given its significant hedge fund backing and attractive upside potential, Stereotaxis, Inc. (NYSEAMERICAN:STXS) is one of the most promising robotics stocks.
Stereotaxis, Inc. (NYSEAMERICAN:STXS) is navigating a pivotal product transition, with fresh regulatory wins and a transformational acquisition reshaping its commercial runway, even as near-term results reflect the costs of that transition.
Last month, Stereotaxis, Inc. (NYSEAMERICAN:STXS) reported first-quarter 2026 results, with revenue of $6.3 million, down from $7.5 million in the prior year period. System revenue came in at $1.3 million and recurring revenue at $5.0 million, compared to $2.0 million and $5.5 million, respectively, in Q1 2025. The company said recurring revenue remains pressured by the wind-down of its legacy Johnson & Johnson catheter relationship, with new proprietary catheters still contributing modestly.
Meanwhile, gross margin for the quarter was 60%, with recurring revenue gross margin at 66% and system gross margin at 39%. Operating loss was $6.0 million, and net loss was $5.9 million, while adjusted operating loss, excluding non-cash charges, was $2.9 million. Stereotaxis, Inc. (NYSEAMERICAN:STXS) ended the quarter with $14.6 million in cash and no debt, and noted that demand for its MAGiC cardiac ablation catheter far exceeds current supply, with manufacturing targeted to reach 500 catheters per month by year-end.
Citizens maintained its “Market Outperform” rating on Stereotaxis, Inc. (NYSEAMERICAN:STXS) with a $4.00 price target, with analyst Daniel Stauder pointing to a compelling razor/razor blade ecosystem as a driver of sustainable growth.
The firm views Stereotaxis, Inc. (NYSEAMERICAN:STXS) as a unique microcap worth owning, citing developing tailwinds for system adoption and improved procedural utilization through 2026 and into 2027. Citizens’ $4.00 target is based on an EV/revenue multiple of roughly 6x to 7x applied to its 2027 total sales estimate of $53 million, a premium multiple the firm considers reasonable given an expected approximately 30% top-line growth profile.
Stereotaxis, Inc. (NYSEAMERICAN:STXS) designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory. Its primary products are the Genesis RMN System, the Odyssey Solution, and other related devices.
While we acknowledge the potential of STXS to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than STXS and that has 100x upside potential, check out our report about the cheapest AI stock.
Click to continue reading and see the 5 most promising robotics stocks now.
Disclosure: None. Follow Insider Monkey on Google News.
